Behavior Change Wheel-Based Music Listening for Chemotherapy-Related Cognitive Impairment in Breast Cancer Patients (BCW-MUSIC)
Effect of a Behavior Change Wheel-Based Music Listening Intervention on Chemotherapy-Related Cognitive Impairment in Breast Cancer Patients: An Assessor-Blinded Randomized Controlled Trial
Breast cancer patients frequently experience chemotherapy-related cognitive impairment (CRCI), which can negatively affect memory, attention, executive function, daily activities, and quality of life. Effective non-pharmacological interventions for CRCI remain limited.
This randomized controlled trial aims to evaluate the effectiveness of a Behavior Change Wheel (BCW)-based music listening intervention in improving cognitive function among breast cancer patients receiving chemotherapy. A total of 90 eligible participants will be randomly assigned in a 1:1 ratio to either a BCW-based music listening intervention group or a routine care control group. Participants in the intervention group will receive a 12-week music listening program in addition to routine care, while participants in the control group will receive routine care alone.
The primary outcome is the change in Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) total score from baseline to the end of the intervention. Secondary outcomes include FACT-Cog subscale scores and PROMIS anxiety and depression scores. This study aims to provide evidence regarding the effectiveness of a theory-based music listening intervention for managing chemotherapy-related cognitive impairment in breast cancer patients.
This study was registered retrospectively after completion of participant enrollment and follow-up.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- The First Affiliated Hospital of Nanjing Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histopathologically confirmed breast cancer.
- Female patients aged 18 years or older.
- Patients receiving chemotherapy with at least six planned cycles.
- Able to understand the study procedures and complete the required questionnaires.
- Provided written informed consent and voluntarily agreed to participate.
Exclusion Criteria:
- Visual, hearing, or speech impairment that may affect participation in the intervention or outcome assessment.
- Cognitive impairment caused by other diseases.
- Metastatic breast cancer or cachexia.
- Receiving other interventions specifically targeting cognitive impairment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: BCW-Based Music Listening Intervention Group
Participants in this group received routine nursing care plus a Behavior Change Wheel-based music listening intervention for 12 weeks.
The intervention included relationship building, health education, family involvement, individualized planning, self-training, behavioral reinforcement, daily music listening, and regular feedback.
Participants were instructed to listen to self-selected music for at least 20 minutes per day.
|
The intervention was a 12-week Behavior Change Wheel-based music listening program provided in addition to routine nursing care.
It included relationship building, health education, family involvement, individualized planning, self-training, behavioral reinforcement, daily music listening, and regular feedback.
Participants were instructed to listen to self-selected music for at least 20 minutes per day throughout the intervention period.
Routine nursing care included health education after chemotherapy, educational materials, symptom management guidance, dietary advice, relaxation training, medication guidance, psychological support, WeChat-based information sharing, and follow-up consultation every two weeks.
|
|
Active Comparator: Routine Care Control Group
Participants in this group received routine nursing care, including health education after chemotherapy, educational materials, symptom management guidance, dietary advice, relaxation training, medication guidance, psychological support, WeChat-based information sharing, and follow-up consultation every two weeks.
|
Routine nursing care included health education after chemotherapy, educational materials, symptom management guidance, dietary advice, relaxation training, medication guidance, psychological support, WeChat-based information sharing, and follow-up consultation every two weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Functional Assessment of Cancer Therapy-Cognitive Function Total Score
Time Frame: Baseline and Week 12
|
The primary outcome was the change in the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) total score from baseline to Week 12.
The FACT-Cog includes 37 items scored on a 0 to 4 Likert scale, with a total score ranging from 0 to 148.
Higher scores indicate better perceived cognitive function.
|
Baseline and Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in FACT-Cog Perceived Cognitive Impairment Subscale Score
Time Frame: Baseline and Week 12
|
Change in the perceived cognitive impairment subscale score of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) from baseline to Week 12. Higher scores indicate better perceived cognitive function.
|
Baseline and Week 12
|
|
Change in FACT-Cog Comments From Others Subscale Score
Time Frame: Baseline and Week 12
|
Change in the comments from others subscale score of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) from baseline to Week 12. Higher scores indicate better perceived cognitive function.
|
Baseline and Week 12
|
|
Change in FACT-Cog Perceived Cognitive Abilities Subscale Score
Time Frame: Baseline and Week 12
|
Change in the perceived cognitive abilities subscale score of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) from baseline to Week 12. Higher scores indicate better perceived cognitive function.
|
Baseline and Week 12
|
|
Change in FACT-Cog Impact on Quality of Life Subscale Score
Time Frame: Baseline and Week 12
|
Change in the impact on quality of life subscale score of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) from baseline to Week 12. Higher scores indicate less impact of cognitive symptoms on quality of life.
|
Baseline and Week 12
|
|
Change in PROMIS Depression Short Form Score
Time Frame: Baseline and Week 12
|
Change in depressive symptoms assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short Form from baseline to Week 12.
The scale includes 8 items scored on a 5-point Likert scale.
Higher scores indicate more severe depressive symptoms.
|
Baseline and Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Neoplasms by Site
- Neoplasms
- Neurocognitive Disorders
- Cognition Disorders
- Chemically-Induced Disorders
- Skin Diseases
- Breast Diseases
- Drug-Related Side Effects and Adverse Reactions
- Cognitive Dysfunction
- Skin and Connective Tissue Diseases
- Chemotherapy-Related Cognitive Impairment
- Breast Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- NMU-BCW-MUSIC-CRCI-2025 (Other Identifier: The First Affiliated Hospital of Nanjing Medical University)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
NCT01372579UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer
-
NCT01292083WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
NCT07331506RecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating Ductal Carcinoma
-
NCT00618657CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast Cancer
-
NCT00407888CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast Cancer
-
NCT00986609CompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer
-
NCT05020860RecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer
-
NCT02580448CompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the Breast
-
NCT02566408CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer
-
NCT00513695CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer
Clinical Trials on BCW-Based Music Listening Intervention
-
NCT05792176CompletedPathologic Processes | Nervous System Diseases | Immune System Diseases | Multiple Sclerosis | Demyelinating Autoimmune Diseases, CNS | Autoimmune Diseases of the Nervous System | Demyelinating Diseases | Autoimmune Diseases
-
NCT07350993Completed
-
NCT07207642Recruiting
-
NCT04157244CompletedNeurocognitive Disorders | Sleep Disorder | Insomnia | Cognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Frontotemporal Dementia | Vascular Dementia | Cognitive Decline
-
NCT06248125RecruitingParenting Intervention
-
NCT07646509RecruitingMedically Unexplained Symptoms | Impairment | Persistent Physical Symptoms | Somatic Symptom Disorder (DSM-5) | Psychological Factors
-
NCT06629675RecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway Disease
-
NCT05243732CompletedDepression | Stress | Anxiety | Visual Impairment | Low Vision | Emotional Adjustment